CVS is opting against covering a twice-yearly injectable HIV prevention drug, drawing criticism from advocates who are ...

CVS Health will not cover Gilead's Yeztugo, generic name lenacapavir (LEN), citing "clinical, financial, and regulatory ...

CVS Health, one of the nation’s largest pharmacy benefit manager companies that play a lead role in deciding which drugs are ...

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

E xecutives at Gilead Sciences, the biotech behind a long list of HIV treatments and preventative medicines, have spoken with ...

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...

Gilead shares slip after CVS refused to add its new HIV drug, Yeztugo, while its Kite unit struck a $350 million deal with ...

Gilead Sciences (NASDAQ:GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE:CVS) will not add the company’s new HIV prevention drug, Yeztugo, to its commercial ...

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...

CVS treatment program discriminates against people with HIV, judge says Apr. 20, 2024 1:04 PM ET CVS Health Corporation (CVS) Stock By: Dulan Lokuwithana, SA News Editor 11 Comments ...

A lawsuit has been filed against CVS Health claiming that it unintentionally revealed the HIV status of 6,000 of its customers in Ohio. In a federal lawsuit filed last Wednesday, three John Does ...